drugset / Trial / NCT01658462
Phase II Study of Docetaxel +/- Nintedanib in Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
National, randomized, unblinded, phase IIb trial with 2 strata: First-line chemotherapy / Second-line chemotherapy for locally recurrent or metastatic breast cancer.
Timeline
- Start
- 2013-05
- Primary completion
- 2016-12-31
- Completion
- 2017-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Subject | Docetaxel | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Nintedanib | Small molecule | 200 mg | Oral |